Diceros Therapeutics
Newton, US · Founded 2022 · Delaware corporation
Diceros Therapeutics develops Verasone, a drug candidate combining two existing therapies for treatment of chronic rhinosinusitis via sinonasal irrigation. The company is advancing the treatment through clinical trials to provide improved efficacy and reduced side effects compared to existing options.
Founders & leadership
SR
Stephen R. SeilerExecutive
Board
IV
Ids van der WeijBoard director
WG
Wyatt GotbetterBoard director
JF
Jonathan FlemingBoard director
Reported raises · per SEC filings
Form D private placements$12.6M disclosed across 1 round · 2022
▶$12.6MraisedAug 2024 · 13 investors · BiotechnologyRule 506(b)
▶$12.6MraisedAug 2024 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen R. SeilerExecutive Officer, Director
- Ids van der WeijDirector
- Wyatt GotbetterDirector
- Jonathan FlemingDirector
- Offering amount
- $18.1M
- Amount sold
- $12.6M
- Proceeds to insiders
- $1M
- First sale
- Sep 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Diceros Therapeutics do?
- Diceros Therapeutics develops Verasone, a drug candidate combining two existing therapies for treatment of chronic rhinosinusitis via sinonasal irrigation. The company is advancing the treatment through clinical trials to provide improved efficacy and reduced side effects compared to existing options.
- How much funding has Diceros Therapeutics raised?
- Diceros Therapeutics has disclosed $12.6M raised across 1 round.
- Where is Diceros Therapeutics headquartered?
- Diceros Therapeutics is headquartered in Newton, US.